rounded-down-pointerchevron-downmenuadd-circleminus-circlelinkedinTwitterrounded-right-pointercrossnext-circleplay-circlethin-down-pointerrounded-left-pointerdownload-circle
Skip to the main content

Evonetix closes $30 million Series B round lead by Foresite Capital to develop a new paradigm for gene synthesis.

Posted on

Congratulations to Evonetix for successfully raising $30 million in their recent Series B round lead by Foresite Capital. Draper Esprit is proud to have participated in the round alongside other existing investors DCVC (Data Collective), the Morningside group Limited, Providence Investment Company, Cambridge Consultants Ltd., Rising Tide Fund and Civilization Ventures.

Evonetix Ltd. is a synthetic biology company developing a desktop platform for scalable, high fidelity and rapid gene synthesis.

We look forward to continuing our partnership with Evonetix as they continue to develop the integration of DNA and technology.

Read the RNS here and the press release here.

Interested in Evonetix? Find out more about them here.